NCT00811564View on ClinicalTrials.gov

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution

1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day

DRUG

latanoprost 0.005%

1 drop of study medication taken once daily

Trial Locations (1)

Unknown

Slingerlands

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT00811564 - An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects | Biotech Hunter | Biotech Hunter